Abstract:The "bubblegum" acyl-CoA synthetase (ACSBG1) is a pivotal player in lipid metabolism during the development of the mouse brain, facilitating the activation of long-chain fatty acids (LCFAs) and their integration into essential lipid species crucial for brain function. Through its enzymatic activity, ACSBG1 converts LCFAs into acyl-CoA derivatives, supporting vital processes like membrane formation, myelination, and energy production. Its regulatory role significantly influences neuronal growth, synaptic plasticity, and overall brain development, highlighting its importance in maintaining lipid homeostasis and proper brain function. Originally discovered in the fruit fly brain, ACSBG1 attracted attention for its potential implication in X-linked adrenoleukodystrophy (XALD) pathogenesis. Studies using Drosophila melanogaster lacking the ACSBG1 homolog, bubblegum, revealed adult neurodegeneration with elevated levels of very long-chain fatty acids (VLCFA). To explore ACSBG1's role in fatty acid (FA) metabolism and its relevance to XALD, we created an ACSBG1 knockout (Acsbg1-/-) mouse model and examined its impact on lipid metabolism during mouse brain development. Phenotypically, Acsbg1-/- mice resembled wild type (w.t.) mice. Despite its primary expression in tissues affected by XALD, brain, adrenal gland and testis, ACSBG1 depletion did not significantly reduce total ACS enzyme activity in these tissues when using LCFA or VLCFA as substrates. However, analysis unveiled intriguing developmental and compositional changes in FA levels associated with ACSBG1 deficiency. In the adult mouse brain, ACSBG1 expression peaked in the cerebellum, with lower levels observed in other brain regions. Developmentally, ACSBG1 expression in the cerebellum was initially low during the first week of life but increased dramatically thereafter. Cerebellar FA levels were assessed in both w.t. and Acsbg1-/- mouse brains throughout development, revealing notable differences. While saturated VLCFA levels were typically high in XALD tissues and in fruit flies lacking ACSBG1, cerebella from Acsbg1-/- mice displayed lower saturated VLCFA levels, especially after about 8 days of age. Additionally, monounsaturated ω9 FA levels exhibited a similar trend as saturated VLCFA, while ω3 polyunsaturated FA levels were elevated in Acsbg1-/- mice. Further analysis of specific FA levels provided additional insights into potential roles for ACSBG1. Notably, the decreased VLCFA levels in Acsbg1-/- mice primarily stemmed from changes in C24:0 and C26:0, while reduced ω9 FA levels were mainly observed in C18:1 and C24:1. ACSBG1 depletion had minimal effects on saturated long-chain FA or ω6 polyunsaturated FA levels but led to significant increases in specific ω3 FA, such as C20:5 and C22:5. Moreover, the impact of ACSBG1 deficiency on the developmental expression of several cerebellar FA metabolism enzymes, including those required for synthesis of ω3 polyunsaturated FA, was assessed; these FA can potentially be converted into bioactive signaling molecules like eicosanoids and docosanoids. In conclusion, despite compelling circumstantial evidence, it is unlikely that ACSBG1 directly contributes to the pathology of XALD. Instead, the effects of ACSBG1 knockout on processes regulated by eicosanoids and/or docosanoids should be further investigated.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the role of "bubblegum" acyl - CoA synthetase (ACSBG1) in mouse brain lipid metabolism and its correlation with the pathogenesis of X - linked adrenoleukodystrophy (XALD). Specifically, researchers created a mouse model with ACSBG1 gene knockout (Acsbg1 - / -) to observe the impact of ACSBG1 deficiency on lipid metabolism, especially during the development of the mouse brain. In addition, the study also aims to evaluate whether ACSBG1 is directly involved in the pathological process of XALD, or whether its influence is manifested through other pathways, for example, by affecting the production of bioactive signaling molecules of eicosanoic and docosanoic fatty acids. ### Main research questions: 1. **The role of ACSBG1 in mouse brain lipid metabolism**: Study how ACSBG1 affects the activation and integration of long - chain and very - long - chain fatty acids (LCFA and VLCFA), and how these processes affect brain function and development. 2. **The relationship between ACSBG1 and XALD**: Explore whether ACSBG1 is directly involved in the pathogenesis of XALD, especially its role in abnormal lipid metabolism in XALD. 3. **Phenotypic analysis of ACSBG1 - knockout mouse model**: By creating and analyzing the ACSBG1 gene - knockout mouse model, observe the changes in lipid metabolism at different developmental stages, especially the changes in the levels of saturated VLCFA and monounsaturated fatty acids (MUFA), and the increase in the level of ω3 polyunsaturated fatty acids (PUFA). ### Research methods: - **Animal model**: Created an ACSBG1 gene - knockout (Acsbg1 - / -) mouse model. - **Lipid analysis**: Used gas chromatography - mass spectrometry (GC/MS) technology to measure the fatty acid composition in mouse brain tissues. - **Gene expression analysis**: Detected the expression levels of ACSBG1 and related lipid - metabolizing enzymes by quantitative real - time PCR (qRT - PCR) and Western blotting. - **Statistical analysis**: Used ANOVA and t - test for statistical analysis to determine the differences in lipid parameters between wild - type and knockout mice. ### Conclusion: Despite the compelling indirect evidence, ACSBG1 may not directly cause the pathology of XALD. Instead, the regulatory role of ACSBG1 knockout on bioactive signaling molecules of eicosanoic and docosanoic fatty acids (such as eicosanoids and docosanoids) is worthy of further study.

Role of ACSBG1 in brain lipid metabolism and X-linked adrenoleukodystrophy pathogenesis: Insights from a knockout mouse model

Role of ACSBG1 in Brain Lipid Metabolism and X-Linked Adrenoleukodystrophy Pathogenesis: Insights from a Knockout Mouse Model

Genetic analysis of the X-linked Adrenoleukodystrophy ABCD1 gene in Drosophila uncovers a role in Peroxisomal dynamics

A Novel Mouse Model for Cerebral Inflammatory Demyelination in X‐Linked Adrenoleukodystrophy: Insights into Pathogenesis and Potential Therapeutic Targets

Acsl, the Drosophila Ortholog of Intellectual-Disability-related ACSL4, Inhibits Synaptic Growth by Altered Lipids.

Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy

Abstract 19596: Endothelial Acyl-CoA Synthetase 1 is not Required for Saturated Fatty Acid- Mediated Inflammatory and Apoptotic Effects

Drug discovery for X-linked adrenoleukodystrophy: An unbiased screen for compounds that lower very long-chain fatty acids

Elovl1 inhibition reduced very long chain fatty acids in a mouse model of adrenoleukodystrophy

Long-chain acyl-CoA synthetase regulates systemic lipid homeostasis via glycosylation-dependent lipoprotein production

From gene to therapy: a review of deciphering the role of ABCD1 in combating X-Linked adrenoleukodystrophy

Analyses of mental dysfunction-related ACSl4 in Drosophila reveal its requirement for Dpp/BMP production and visual wiring in the brain.

Activation of Liver X Receptor Β-Enhancing Neurogenesis Ameliorates Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion.

Microglia-Dependent and Independent Modulation of Brain Lipid Metabolism in Alzheimer's Disease Revealed by Pharmacological and Genetic Microglial Depletion

Antioxidant Response in Human X-Linked Adrenoleukodystrophy Fibroblasts

Ataxia with giant axonopathy in Acbd5-deficient mice halted by adeno-associated virus gene therapy

Two Single Nucleotide Deletions in the ABCD1 Gene Causing Distinct Phenotypes of X-Linked Adrenoleukodystrophy

Metabolic Enzyme Alterations and Astrocyte Dysfunction in a Murine Model of Alexander Disease With Severe Reactive Gliosis

Lipidomic biomarkers in plasma correlate with disease severity in adrenoleukodystrophy

Oxidative Imbalance, Nitrative Stress, and Inflammation in C6 Glial Cells Exposed to Hexacosanoic Acid: Protective Effect of N-acetyl-l-cysteine, Trolox, and Rosuvastatin

Modeling and rescue of defective blood-brain barrier function of induced brain microvascular endothelial cells from childhood cerebral adrenoleukodystrophy patients